Apthera, Inc. Announces Optimal Dose And Schedule Of Neuvax For Phase III Clinical Trial In Breast Cancer
Published: Oct 01, 2008
SCOTTSDALE, Ariz.--(BUSINESS WIRE)--Apthera, Inc. announced the optimized dose and schedule for its lead drug, NeuVax, in treating early-stage breast cancer patients to be used in Phase III clinical trials. Dr. George Peoples, Deputy Director, United States Military Cancer Center, co-authored a publication that appears on the cover of the October 1, 2008, issue of Cancer (Vol.113 Issue 7:1666-75) and details the Phase I/II clinical study results.